459 results on '"Cheng, Pin‐Nan"'
Search Results
2. Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals
3. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
4. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
5. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
6. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection
7. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
8. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes
9. Interdependence of glycemic and lipid modulation in cured chronic hepatitis C patients by direct-acting antiviral agents
10. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
11. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
12. THU-365 Real-world effectiveness and safety of 8-week glecaprevir/ pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry
13. OS-121 Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis
14. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
15. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial
16. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
17. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
18. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
19. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
20. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
21. Structural Polymorphs Suggest Competing Pathways for the Formation of Amyloid Fibrils That Diverge from a Common Intermediate Species.
22. Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium‐90 resin microspheres in Taiwan: data from the RESIN registry
23. Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients”
24. The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan
25. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
26. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
27. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
28. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
29. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
30. Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease
31. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early‐stage hepatocellular carcinoma: a propensity score matching analysis
32. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
33. Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals
34. Artificial intelligence predicts direct-acting antivirals failure among HCV patients: A Nationwide HCV Registry Program
35. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
36. Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment
37. Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet
38. Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity
39. The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry
40. Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B
41. Effect of Tenofovir and Entecavir on occurrence of hepatocellular carcinoma depends on duration of antiviral treatment and hierarchical PAGE-B risk score
42. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan
43. Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switchingto tenofovir alafenamide in chronic hepatitis B patients
44. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
45. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
46. Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
47. Post-therapeutic reversibility of oxidative-stress markers in chronic hepatitis C patients receiving direct-acting antiviral agents
48. Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysis
49. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
50. THU-174 - The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.